DOI QR코드

DOI QR Code

Subtype-Based Microbial Analysis in Non-small Cell Lung Cancer

  • Hye Jin Jang (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine) ;
  • Eunkyung Lee (Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology) ;
  • Young-Jae Cho (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Sang Hoon Lee (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine)
  • Received : 2022.11.18
  • Accepted : 2023.06.18
  • Published : 2023.10.31

Abstract

Background: The human lung serves as a niche for a unique and dynamic bacterial community related to the development and aggravation of multiple respiratory diseases. Therefore, identifying the microbiome status is crucial to maintaining the microecological balance and maximizing the therapeutic effect on lung diseases. Therefore, we investigated the histological type-based differences in the lung microbiomes of patients with lung cancer. Methods: We performed 16S rRNA sequencing to evaluate the respiratory tract microbiome present in bronchoalveolar lavage fluid. Patients with non-small cell lung cancer were stratified based on two main subtypes of lung cancer: adenocarcinoma and squamous cell carcinoma (SqCC). Results: Among the 84 patients analyzed, 64 (76.2%) had adenocarcinoma, and 20 (23.8%) had SqCC. The α- and β-diversities showed significant differences between the two groups (p=0.004 for Chao1, p=0.001 for Simpson index, and p=0.011 for PERMANOVA). Actinomyces graevenitzii was dominant in the SqCC group (linear discriminant analysis [LDA] score, 2.46); the populations of Haemophilus parainfluenza (LDA score, 4.08), Neisseria subflava (LDA score, 4.07), Porphyromonas endodontalis (LDA score, 3.88), and Fusobacterium nucleatum (LDA score, 3.72) were significantly higher in the adenocarcinoma group. Conclusion: Microbiome diversity is crucial for maintaining homeostasis in the lung environment, and dysbiosis may be related to the development and prognosis of lung cancer. The mortality rate was high, and the microbiome was not diverse in SqCC. Further large-scale studies are required to investigate the role of the microbiome in the development of different lung cancer types.

Keywords

Acknowledgement

This Study was Supported by a 2021-Grant from The Korean Academy of Tuberculosis and Respiratory Diseases.

References

  1. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered?: revisiting the ratio of bacterial to host cells in humans. Cell 2016;164:337-40.  https://doi.org/10.1016/j.cell.2016.01.013
  2. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res 2020;30:492-506.  https://doi.org/10.1038/s41422-020-0332-7
  3. Jubinville E, Veillette M, Milot J, Maltais F, Comeau AM, Levesque RC, et al. Exacerbation induces a microbiota shift in sputa of COPD patients. PLoS One 2018;13:e0194355. 
  4. Naidoo CC, Nyawo GR, Wu BG, Walzl G, Warren RM, Segal LN, et al. The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. Lancet Respir Med 2019;7:892-906.  https://doi.org/10.1016/S2213-2600(18)30501-0
  5. Kitsios GD, Rojas M, Kass DJ, Fitch A, Sembrat JC, Qin S, et al. Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with endstage fibrosis. Thorax 2018;73:481-4.  https://doi.org/10.1136/thoraxjnl-2017-210537
  6. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell 2016;165:276-87.  https://doi.org/10.1016/j.cell.2016.03.001
  7. Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, et al. PARP1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterial toxin microcystin. Front Microbiol 2018;9:1757. 
  8. Ramirez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, et al. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer 2020;6:86-97.  https://doi.org/10.1016/j.trecan.2019.12.007
  9. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 2015;4:327-38. 
  10. Brandi G, Frega G. Microbiota: overview and implication in immunotherapy-based cancer treatments. Int J Mol Sci 2019;20:2699. 
  11. Liu NN, Ma Q, Ge Y, Yi CX, Wei LQ, Tan JC, et al. Microbiome dysbiosis in lung cancer: from composition to therapy. NPJ Precis Oncol 2020;4:33. 
  12. Cameron SJ, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, et al. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One 2017;12:e0177062. 
  13. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 2016;5:288-300.  https://doi.org/10.21037/tlcr.2016.06.07
  14. Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT, Carter BW. Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer. Radiol Clin North Am 2018;56:485-95.  https://doi.org/10.1016/j.rcl.2018.01.012
  15. Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol 2022;13:823618. 
  16. Blach J, Wojas-Krawczyk K, Nicos M, Krawczyk P. Failure of immunotherapy: the molecular and immunological origin of immunotherapy resistance in lung cancer. Int J Mol Sci 2021;22:9030. 
  17. Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013;68 Suppl 1:i1-44.  https://doi.org/10.1136/thoraxjnl-2013-203618
  18. Willis AD. Rarefaction, alpha diversity, and statistics. Front Microbiol 2019;10:2407. 
  19. Goodrich JK, Di Rienzi SC, Poole AC, Koren O, Walters WA, Caporaso JG, et al. Conducting a microbiome study. Cell 2014;158:250-62.  https://doi.org/10.1016/j.cell.2014.06.037
  20. Kovaleva OV, Romashin D, Zborovskaya IB, Davydov MM, Shogenov MS, Gratchev A. Human lung microbiome on the way to cancer. J Immunol Res 2019;2019:1394191. 
  21. Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin Immunol 2017;32:25-34.  https://doi.org/10.1016/j.smim.2017.08.001
  22. Segal LN, Clemente JC, Tsay JC, Koralov SB, Keller BC, Wu BG, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol 2016;1:16031. 
  23. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra25. 
  24. Tufvesson E, Bjermer L, Ekberg M. Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation. Int J Chron Obstruct Pulmon Dis 2015;10:881-9.  https://doi.org/10.2147/COPD.S78748
  25. Kosikowska U, Biernasiuk A, Rybojad P, Los R, Malm A. Haemophilus parainfluenzae as a marker of the upper respiratory tract microbiota changes under the influence of preoperative prophylaxis with or without postoperative treatment in patients with lung cancer. BMC Microbiol 2016;16:62. 
  26. Druzhinin VG, Matskova LV, Demenkov PS, Baranova ED, Volobaev VP, Minina VI, et al. Taxonomic diversity of sputum microbiome in lung cancer patients and its relationship with chromosomal aberrations in blood lymphocytes. Sci Rep 2020;10:9681. 
  27. Olsen I, Yilmaz O. Possible role of Porphyromonas gingivalis in orodigestive cancers. J Oral Microbiol 2019;11:1563410. 
  28. Schaad UB. Arthritis in disease due to Neisseria meningitidis. Rev Infect Dis 1980;2:880-8.  https://doi.org/10.1093/clinids/2.6.880
  29. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, et al. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 1993;328:21-8.  https://doi.org/10.1056/NEJM199301073280104
  30. Al-Hebshi NN, Nasher AT, Idris AM, Chen T. Robust species taxonomy assignment algorithm for 16S rRNA NGS reads: application to oral carcinoma samples. J Oral Microbiol 2015;7:28934. 
  31. Su SC, Chang LC, Huang HD, Peng CY, Chuang CY, Chen YT, et al. Oral microbial dysbiosis and its performance in predicting oral cancer. Carcinogenesis 2021;42:127-35.  https://doi.org/10.1093/carcin/bgaa062
  32. Binder Gallimidi A, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM, et al. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget 2015;6:22613-23.  https://doi.org/10.18632/oncotarget.4209
  33. Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res 2016;22:5574-81.  https://doi.org/10.1158/1078-0432.CCR-16-1786
  34. Xu N, Wang L, Li C, Ding C, Li C, Fan W, et al. Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms. Transl Lung Cancer Res 2020;9:1554-68.  https://doi.org/10.21037/tlcr-20-156
  35. Shiels MS, Albanes D, Virtamo J, Engels EA. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 2011;20:672-8.  https://doi.org/10.1158/1055-9965.EPI-10-1166
  36. Arulanantham A, Jayarajah U, Dharmasiri R, Jeyanthakumar R, Siriwardena KN, Ilangamge S. Squamous cell carcinoma in the post tuberculosis lung after 30 years of treatment completion. Case Rep Surg 2020;2020:8570212. 
  37. Gliga S, Devaux M, Gosset Woimant M, Mompoint D, Perronne C, Davido B. Actinomyces graevenitzii pulmonary abscess mimicking tuberculosis in a healthy young man. Can Respir J 2014;21:e75-7.  https://doi.org/10.1155/2014/841480
  38. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:497-530.  https://doi.org/10.6004/jnccn.2022.0025
  39. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol 2020;146:43-52. https://doi.org/10.1007/s00432-019-03079-8